title: Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
authors.affiliation: Division of Medical Oncology, School of Medicine, University of Washington Medical Center, Seattle, WA, USA. hmlinden@u.washington.edu
authors.forename: Hannah M
authors.initials: HM
authors.lastname: Linden
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Krohn
authors.forename: Robert B
authors.initials: RB
authors.lastname: Livingston
authors.forename: David A
authors.initials: DA
authors.lastname: Mankoff
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D019788:Fluorodeoxyglucose F18; D000077156:Gefitinib; D005947:Glucose / Q000493:pharmacokinetics; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011799:Quinazolines / Q000627:therapeutic use*; D011877:Radionuclide Imaging
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D019788:Fluorodeoxyglucose F18; D066246:ErbB Receptors; D005947:Glucose; D000077156:Gefitinib